LifeTech Scientific Corporation(LFTSF)

$0.23—

Chart

LifeTech Scientific Corporation(LFTSF)

OTCMARKET

$0.23—

Chart Studio

LFTSF(LFTSF)

LFTSF

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

7/20/26

LIFETECH SCIENTIFIC (LFTSF)

Monday

12:01 PM

Thesis: Recent regulatory approvals and strategic partnerships are enhancing LifeTech's growth prospects, particularly in international markets.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$1.4B	$1.5B	$1.7B
Rev. Growth	+5.1%	+9.6%	+13.6%
EPS	$0.03	$0.08	$0.11
EPS Growth	-33.3%	+131%	+37.5%
P/E (fwd)	6.9×	3.0×	2.2×

★ Analysts see FY2027 revenue reaching $1.7B — +13.6% growth in a single year.

The Bull Case for Growth

1LifeTech's new cardiovascular device received FDA approval, potentially increasing U.S. market access by 25%.
2Recent partnerships with hospitals in Southeast Asia could drive a 15% increase in regional sales over the next 12 months.
3R&D pipeline includes three new products targeting orthopedic applications, expected to launch within the next year.
4Digital health integration in medical devices
5Growing demand for minimally invasive surgical solutions
6Regulatory approvals for new medical devices in China and Europe
7Market penetration rates in emerging markets, particularly Southeast Asia
8Changes in healthcare policies affecting medical device reimbursement

FY2025 Snapshot

Revenue: $1.4B
Rev. Growth: +5.1%
Gross Margin: 74.4%
Op. Margin: 12.8%
Net Margin: 10.8%
Net Income: $148M
NI Growth: -33.5%
EPS: $0.03
1Y Return: +0.0%

LFTSF Chart

My Notes

"Our commitment to innovation and market expansion is driving our growth strategy forward."
Moat: LifeTech's proprietary technologies and established market presence provide a moderate level of competitive advantage.
growth - Investors seeking exposure to innovative healthcare solutions and emerging markets will find LifeTech appealing.
Low - LifeTech's business model is not heavily reliant on debt financing, and interest rate changes have minimal impact on its operational…
Watch on earnings: Regulatory approval timelines for new devices, Market share in the cardiovascular segment, R&D expenditure as a percentage of revenue.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $1.5B to $1.7B as lifetech's new cardiovascular device received fda approval, potentially increasing u.s.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

P/E (fwd)

6.9×

3.0×

2.2×

The Bull Case for Growth

1LifeTech's new cardiovascular device received FDA approval, potentially increasing U.S. market access by 25%.

2Recent partnerships with hospitals in Southeast Asia could drive a 15% increase in regional sales over the next 12 months.

3R&D pipeline includes three new products targeting orthopedic applications, expected to launch within the next year.

4Digital health integration in medical devices

5Growing demand for minimally invasive surgical solutions

6Regulatory approvals for new medical devices in China and Europe

7Market penetration rates in emerging markets, particularly Southeast Asia

8Changes in healthcare policies affecting medical device reimbursement

My Notes

"Our commitment to innovation and market expansion is driving our growth strategy forward."

Moat: LifeTech's proprietary technologies and established market presence provide a moderate level of competitive advantage.

growth - Investors seeking exposure to innovative healthcare solutions and emerging markets will find LifeTech appealing.

Low - LifeTech's business model is not heavily reliant on debt financing, and interest rate changes have minimal impact on its operational…

Watch on earnings: Regulatory approval timelines for new devices, Market share in the cardiovascular segment, R&D expenditure as a percentage of revenue.